Peptide and non-peptide bradykinin receptor antagonists: Role in allergic airway disease

• Published in: European journal of pharmacology 2006-03, Vol.533 (1-3), p.215-221
• Main Authors: Abraham, William M., Scuri, Mario, Farmer, Stephen G.
• Format: Article
• Language: English
• Subjects: Airway inflammation; Animal model; Animals; Anti-Inflammatory Agents, Non-Steroidal - pharmacology; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Asthma; Asthma - drug therapy; Asthma - metabolism; Bradykinin - analogs & derivatives; Bradykinin - metabolism; Bradykinin - pharmacology; Bradykinin - therapeutic use; Bradykinin B2 Receptor Antagonists; Disease Models, Animal; Humans; Kinin; Quinolines - pharmacology; Quinolines - therapeutic use; Receptor, Bradykinin B2 - metabolism; Respiratory System - drug effects; Respiratory System - metabolism; Therapy; Tissue Kallikreins - metabolism
• ISSN: 0014-2999; 1879-0712
• DOI: 10.1016/j.ejphar.2005.12.071

Kinins are proinflammatory peptides that mediate a variety of pathophysiological responses. These actions occur through stimulation of two pharmacologically distinct receptor subtypes B1 and B2. In both human and animal airways, the majority of kinin-induced effects including bronchoconstriction, increases in vascular permeability and mucus secretion and cholinergic and sensory nerve stimulation appear to be bradykinin B2-receptor mediated. Peptidic and non-peptidic receptor antagonists have been developed as potential therapeutic agents. These antagonists are effective in blocking kinin-induced effects in a variety of animal models and in some instances, have been used effectively in animal models of allergic airway disease to alleviate allergen-induced pathophysiological airway responses. This review summarizes relevant studies supporting the evidence that bradykinin B2 receptor antagonism and/or upstream inhibition of tissue kallikrein will be beneficial in the treatment of inflammatory airway diseases.